|
GDMT’s Financial Benefits, Good Vibrations, and Cardiac AI Approvals
June 22, 2026
|
|
|
|
|
Together with
|
|
|
|
“Frankly, over-adherence to guidelines may presage the loss of the art of medicine, not taking in the human factor of each patient, and the human-to-human bond that would be the foundation of the patient-doctor relationship.”
|
|
Eric Topol, MD, on guidelines in AI tools for doctors.
|
|
|
Guidelines are often important for giving patients the best chance at the best outcomes. Today’s top story also suggests that HFrEF medical therapy guidelines benefit hospitals’ bottom-lines, which is a rare win-win.
Cheers and thanks for reading,
Vik
|
|
|
|
The four-drug guidelines for heart failure with reduced ejection fraction are well established to cut hospitalizations and a new economic analysis in JAMA suggests that the hospital cost-savings more than cover the cost of the drugs themselves.
- Quadruple GDMT for HFrEF (combining ARNIs, beta-blockers, MRAs, and SGLT2is) has strong data backing its ability to reduce hospitalizations.
- However, the combined financial impact of implementing the full regimen after a hospitalization hasn’t been quantified until now.
To model the cost offset of applying GDMT, researchers analyzed Medicare-linked cost data across 50.5k hospitalized HFrEF patients aged 65+ with one year of post-discharge follow-up.
- On average, the one-year total healthcare costs were $41,802 per patient, with $25,172 of that due to all-cause hospitalizations.
Researchers then projected the financial impact of fewer hospitalizations from GDMT.
- Quadruple GDMT was associated with an 87% relative reduction in HF hospitalizations and a 61% reduction in all-cause hospitalizations.
- That translated to $9,780 in lower hospitalization-associated expenditures per patient annually (a 23.4% relative cost reduction).
More specifically, the net cost decrease depended almost entirely on drug pricing, which is where things get more complicated
- Annual drug costs ranged widely (from $1,223 to $16,136) depending on the pricing source and specific agents used within each class.
- The resulting net annual figure ranged from $8,556 in savings to $6,347 in added net cost, with most four-drug combos leading to net savings.
That means the drug selection determines the economics.
- When clinicians can access lower-cost agents within each drug class (particularly generics) quadruple therapy becomes cost-saving.
The Takeaway
Quadruple GDMT doesn’t just lead to better HFrEF outcomes, it leads to lower financial burden on hospitals, and ultimately the healthcare system. That’s a win for everyone from the payor to the patient, meaning there’s probably no reason to not follow these guidelines.
|
|
The Unified Cardiac Workflow
Cardiovascular disease remains the leading cause of global mortality, yet diagnostic workflows remain fragmented. That’s why it’s so important that Circle Cardiovascular Imaging’s cvi42 is the industry’s first unified platform for reading Cardiac MRI and Cardiac CT, and PCAT analysis within a single application.
|
|
How Automated MRI Software Transformed Radiology Regional
Radiology Regional recently integrated automated MRI scanning software into their imaging practice imaging. Hear from their team how automating CMR scans streamlined their practice and enhanced patient care.
|
|
CathWorks is now part of Medtronic.
The CathWorks FFRangio™ system is the new standard in coronary physiology. Learn more.
Source: Fearon WF, Jeremias A, Witberg G, et al. Angiography-Derived Fractional Flow Reserve to Guide PCI. NEJM 2026. doi: 10.1056/NEJMoa2600949
|
|
- Cardiology AI Keeps Climbing: The FDA cleared another 22 AI algorithms for cardiology, bringing the specialty’s total to 225. That count comprises 146 listed specifically under cardiology and 69 more for cardiovascular imaging, keeping cardiology in the No. 2 spot behind only radiology. The newly cleared cardiovascular AI models span a wide range of uses, from improving cath lab angiography to EP ablation guidance and automated echo quantification. The new additions to the list include AI software from vendors like Anumana, Boston Scientific, Philips, Aidoc, AliveCor, GE, Canon, and Bunkerhill.
- Good Vibrations for Lead Extraction: Researchers tested a promising new vibration-based technique for removing implanted EP device leads that have become encased in vessel walls. Tested successfully in 10 patients, the new tech uses a thin guide wire locking stylet that inserts into the implanted lead to deliver vibrations. This loosens the lead from surrounding scar tissue, allowing removal with less resistance which helps avoid the risks of vessel perforation, bleeding, and collateral tissue damage that are common with current cutting and laser tools.
- No Bicarb Boost in Cardiac Arrest: It turns out that sodium bicarbonate (baking soda) doesn’t improve spontaneous circulation in patients with in-hospital cardiac arrest. Danish researchers randomized 770 patients to either bicarb or placebo, finding that the sustained return of spontaneous circulation occurred in 39% of patients versus 37% with placebo. Furthermore, 30-day survival and neurological outcomes showed no significant difference. These results suggest it might be time to reconsider routinely giving sodium bicarbonate to in-hospital cardiac arrest patients.
- Medline Adhesive Recall: The FDA issued a Class II recall for nearly 50k of Medline’s procedure kits used in the cardiac cath lab and elsewhere in hospitals due to a problem with the Mastisol Liquid Adhesive included in them. The adhesive, which is used to secure dressings, tapes, and devices over long periods, currently carries a risk of its packaging cracking, rendering it unusable. Affected kits include the Minor Cath Lab Pack, OR Vascular Angio Pack, Port-a-Cath kits, and numerous pacemaker/EP access packs.
- WWE Athletes’ Hearts: A new study offers a rare look at cardiac adaptation in WWE wrestlers finding that despite their size and muscle mass, their hearts are pretty normal. Researchers analyzed electrical and structural remodeling in 68 WWE athletes, finding that ECG abnormalities appeared in just 3%, and LV geometry was normal in 89% of men and 95% of women, with concentric remodeling in only 9%. These findings contrast other studies which have found bodybuilders, who carry similar muscle mass, to have much worse cardiovascular health.
- Florida’s First Staged Septation: The cardiovascular surgery team at Nicklaus Children’s Hospital’s Heart Institute performed Florida’s first staged cardiac septation. Operating on a 1-year-old baby, the surgeons created two functioning ventricles out of one to help oxygen-rich and oxygen-poor blood move effectively while allowing the baby’s heart to keep growing over time. The procedure was part of NIH-backed congenital heart research addressing heart defects that affect nearly 1% of U.S. newborns, or roughly 40,000 infants a year.
- A $400M Cardiac IPO: Kardigan, a clinical-stage precision cardiovascular therapeutics company, priced its IPO of 25M shares at $16 apiece, for expected gross proceeds of $400M before discounts and expenses. The massive IPO will help fund Kardigan’s current cardiovascular pipelines for diseases that have no approved treatment such as: danicamtiv for genetic dilated cardiomyopathy, ataciguat for moderate calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension.
- CRISPR for Cholesterol: Scribe Therapeutics won more than $25M in multi-year grants from the California Institute for Regenerative Medicine to advance two preclinical CRISPR-based cardiometabolic therapies. The first, STX-1200, targets the LPA gene to lower lipoprotein(a). The second, STX-1400, targets APOC3 to lower triglyceride-rich lipoproteins. Both programs leverage Scribe’s X-Editor platform with the goal of becoming single-dose genetic medicines alongside the company’s lead therapy, STX-1150, in a bid to target the lipid drivers of cardiovascular disease.
- The Clock Is Ticking on HCM: One Cleveland Clinic analysis now suggests that time is of the essence when it comes to myectomy for obstructive hypertrophic cardiomyopathy (HCM). Current guidelines advise waiting until symptoms become aggressive to perform surgery, but the study found that the worse the symptoms, the worse surgical outcomes are. Beyond symptoms, women faced a 52% higher risk of negative outcomes, leading authors to argue that NYHA class II symptoms should be a trigger to discuss surgery rather than relying on symptom management.
- Edgewise Shows nHCM Promise: Just a few weeks after selling off its muscular dystrophy segment, Edgewise Therapeutics announced positive topline data from the Phase 2 trial of its nonobstructive HCM drug, EDG-7500. Per the study, patients with nHCM receiving EDG-7500 demonstrated diastolic and symptomatic improvement at 12 weeks. This included approximately 65% mean reduction in NT-proBNP, with 88% of patients achieving normalization or a ≥50% reduction from baseline. These same patients also saw a 13-point average increase in KCCQ score with no adverse side effects.
- Strength Training’s Heart Payoff for Women: An analysis of two Nurses’ Health Study cohorts suggests that routine resistance training meaningfully lowers cardiovascular risk in women. Following 117k female nurses for 14.5 years, researchers found that women doing about two hours of resistance training per week had a 20% lower risk of major CV events and a 44% lower risk of MI versus those doing none. Furthermore, each additional weekly hour of training beyond this further cut major CVD and MI risk by 5% and 14%, respectively.
|
|
9 Merge Cardio Features to Change Your Cardiology Workflows
Having the right tools is essential for efficient cardiology imaging workflows and delivering exceptional patient care. Read this article on how Merge Cardio can make the biggest difference to your imaging workflows, care team user experiences, and patient care delivery.
|
|
State-of-the-Art Cardiac Monitoring at Scale
Cleared for 13 different heart rhythm interpretations, AccurKardia’s AccurECG 2.0 shortens the time from an arrhythmia incident to clinical intervention. Watch here to find out how AccurKardia and Specialized Medical are teaming up to bring the AccurECG 2.0 technology to clinicians across the U.S.
|
|
The Power of AI in Cardiovascular Imaging
Cardiac labs are under more pressure than ever to deliver more with greater speed and precision. Hear from Tony Gallagher, Director of Noninvasive Cardiology at Baptist Health Lexington about how Siemens Healthineers’ ACUSON Origin is reshaping daily practice and transforming the future of echocardiography.
|
|
- Staying ALERT with Tempus: Undertreatment and time to treatment of valvular heart disease are among the biggest challenges health systems face today, but Tempus’ AI-driven EHR notifications can change that. Read the results of Medtronic and Tempus’ ALERT trial which found that delivering data directly to providers resulted in a 40% relative increase in life-saving valve procedures.
- The Economics of AI-Assisted HF Diagnosis: As sonographer shortages become more common, so too are diagnostic delays and missed opportunities for early heart failure treatment. Find out how task-shifting LVEF assessment to novice operators using AI-assisted ultrasound is both clinically viable and cost-saving.
- Making the Leap to Outsource Post-Processing: Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
- Earlier Detection, Better Outcomes: When it comes to heart disease, early detection is crucial to a patient’s long-term health. Learn more about how Fujifilm helps clinicians achieve that with the Lisendo 880 cardiovascular ultrasound system’s unique solutions that detect early abnormalities seen in heart failure, while offering insight into cardiac functions and groundbreaking hemodynamic analysis.
- Telemedicine Isn’t About Technology. It’s About People. With temporary telehealth rules expiring, millions of Medicare patients may lose their ability to see their doctors remotely. Read why Monebo and the Alliance for Connected Care are urging Congress to make telemedicine a permanent part of the healthcare system.
- Changes in Heart Failure Management: Heart failure is a complex condition with high heart failure hospitalization and cardiovascular mortality rates, especially among patients with HFpEF and HFmrEF, for whom treatment options have been limited. Read how Bayer’s Dr. Alanna Morris-Simon discusses the changing treatment landscape and strategies for improving patient outcomes.
|
|
|
|
|
